HONG KONG, Sep 01, 2011 (MARKETWIRE via COMTEX) -- Today, www.WorldStreetFundamentals.com released its industry report highlighting Sinovac Biotech Ltd.  (SVA.NSDQ)and Pharmasset, Inc. (RCode:VRUS:)Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php .

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

World Street Fundamentals has highlighted Sinovac Biotech Ltd. as a holding company that conducts its business in China through its 71.56% majority owned subsidiary, Sinovac Beijing, its wholly owned subsidiaries, Tangshan Yian, Sinovac Biological and Sinovac Hong Kong, and its 30%-owned joint venture Sinovac Dalian. The entire report on Sinovac Biotech Ltd. /quotes/zigman/91613/quotes/nls/sva SVA -6.99% is available here: www.WorldStreetFundamentals.com/ViewFullReport.245.php .

World Street has featured Pharmasset, Inc. as a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The entire report on Pharmasset, Inc. /quotes/zigman/101019/quotes/nls/vrus VRUS -0.66% is available here: www.WorldStreetFundamentals.com/ViewFullReport.138.php .